$105.09
-1.38-1.30%
At Close: -
$105.09
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Jazz Pharmaceuticals
JAZZNASDAQ
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock, Analyst Ratings, Price Targets, Predictions
Jazz Pharmaceuticals PLC has a consensus price target of $179.84, established from looking at the 68 latest analyst ratings. The last 3 analyst ratings were released from UBS, Needham, and Goldman Sachs on July 2, 2024, June 20, 2024, and June 5, 2024. With an average price target of $164 between UBS, Needham, and Goldman Sachs, there's an implied 56.06% upside for Jazz Pharmaceuticals PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
Needham
Goldman Sachs
HC Wainwright & Co.
Barclays
1calculated from analyst ratings
Analyst Ratings for Jazz Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | Buy Now | 7.53% | UBS | Ashwani Verma | $117 → $113 | Maintains | Neutral | Get Alert |
| 06/20/2024 | Buy Now | 99.83% | Needham | Ami Fadia | $222 → $210 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | 60.81% | Goldman Sachs | Madhu Kumar | → $169 | Initiates | → Buy | Get Alert |
| 05/03/2024 | Buy Now | 90.31% | HC Wainwright & Co. | Oren Livnat | → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 90.31% | Barclays | Balaji Prasad | $230 → $200 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 111.25% | Needham | Ami Fadia | → $222 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 71.28% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | Buy Now | 80.8% | JP Morgan | Jessica Fye | $170 → $190 | Maintains | Overweight | Get Alert |
| 03/22/2024 | Buy Now | 71.28% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 90.31% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 78.89% | Piper Sandler | David Amsellem | $171 → $188 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 109.34% | Needham | Ami Fadia | → $220 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 118.86% | Stifel | Annabel Samimy | $225 → $230 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 90.31% | HC Wainwright & Co. | Oren Livnat | $204 → $200 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 118.86% | Barclays | Balaji Prasad | $235 → $230 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 24.66% | UBS | Ashwani Verma | $135 → $131 | Maintains | Neutral | Get Alert |
| 02/29/2024 | Buy Now | 71.28% | Cantor Fitzgerald | Charles Duncan | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | Buy Now | 85.56% | RBC Capital | Gregory Renza | → $195 | Reiterates | Outperform → Outperform | Get Alert |
| 02/29/2024 | Buy Now | 61.77% | JP Morgan | Jessica Fye | $180 → $170 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 109.34% | Needham | Ami Fadia | $225 → $220 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 123.62% | Barclays | Balaji Prasad | $240 → $235 | Maintains | Overweight | Get Alert |
| 01/03/2024 | Buy Now | 52.25% | Baird | Joel Beatty | → $160 | Initiates | → Outperform | Get Alert |
| 12/04/2023 | Buy Now | 90.31% | Truist Securities | Joon Lee | → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/29/2023 | Buy Now | 114.1% | Needham | Ami Fadia | → $225 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 28.46% | UBS | Ashwani Verma | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2023 | Buy Now | 81.75% | RBC Capital | Gregory Renza | $200 → $191 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | 114.1% | Needham | Ami Fadia | $226 → $225 | Maintains | Buy | Get Alert |
| 09/29/2023 | Buy Now | — | Raymond James | Gary Nachman | — | Initiates | → Market Perform | Get Alert |
| 08/22/2023 | Buy Now | 71.28% | Cantor Fitzgerald | Brandon Folkes | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | 71.28% | Cantor Fitzgerald | Brandon Folkes | $210 → $180 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 94.12% | HC Wainwright & Co. | Oren Livnat | → $204 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 106.49% | B of A Securities | Jason Gerberry | $204 → $217 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 91.26% | RBC Capital | Gregory Renza | $203 → $201 | Maintains | Outperform | Get Alert |
| 08/10/2023 | Buy Now | 115.05% | Needham | Ami Fadia | → $226 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 115.05% | Needham | Ami Fadia | → $226 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 77.94% | Morgan Stanley | Jeffrey Hung | $187 → $187 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/05/2023 | Buy Now | 115.05% | Needham | Ami Fadia | → $226 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 115.05% | Needham | Ami Fadia | $212 → $226 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 94.12% | HC Wainwright & Co. | Oren Livnat | → $204 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 101.73% | Needham | Ami Fadia | → $212 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 92.22% | RBC Capital | Gregory Renza | $207 → $202 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 101.73% | Needham | Ami Fadia | $205 → $212 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 94.12% | HC Wainwright & Co. | Oren Livnat | → $204 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 101.73% | Goldman Sachs | Madhu Kumar | $190 → $212 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 95.07% | Needham | Ami Fadia | $210 → $205 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | 80.8% | Goldman Sachs | Madhu Kumar | $192 → $190 | Upgrade | Neutral → Buy | Get Alert |
| 11/10/2022 | Buy Now | 82.7% | Goldman Sachs | Madhu Kumar | $170 → $192 | Maintains | Neutral | Get Alert |
| 11/10/2022 | Buy Now | 96.97% | RBC Capital | Gregory Renza | $206 → $207 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 97.93% | Needham | Ami Fadia | $210 → $208 | Maintains | Buy | Get Alert |
| 09/29/2022 | Buy Now | 61.77% | Goldman Sachs | Madhu Kumar | $148 → $170 | Maintains | Neutral | Get Alert |
| 09/21/2022 | Buy Now | 40.83% | Goldman Sachs | Madhu Kumar | $192 → $148 | Maintains | Neutral | Get Alert |
| 08/04/2022 | Buy Now | 78.89% | BMO Capital | Gary Nachman | $185 → $188 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 77.94% | Morgan Stanley | Jeffrey Hung | $174 → $187 | Maintains | Equal-Weight | Get Alert |
| 08/04/2022 | Buy Now | 81.75% | UBS | Ashwani Verma | $194 → $191 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | 99.83% | SVB Leerink | Marc Goodman | $200 → $210 | Maintains | Outperform | Get Alert |
| 06/14/2022 | Buy Now | 84.6% | UBS | Ashwani Verma | → $194 | Initiates | → Buy | Get Alert |
| 05/05/2022 | Buy Now | 97.93% | RBC Capital | Gregory Renza | $210 → $208 | Maintains | Outperform | Get Alert |
| 05/05/2022 | Buy Now | 83.65% | Piper Sandler | David Amsellem | $197 → $193 | Maintains | Overweight | Get Alert |
| 04/06/2022 | Buy Now | 86.51% | Goldman Sachs | Madhu Kumar | $202 → $196 | Downgrade | Buy → Neutral | Get Alert |
| 03/03/2022 | Buy Now | 104.59% | HC Wainwright & Co. | Oren Livnat | $210 → $215 | Maintains | Buy | Get Alert |
| 03/02/2022 | Buy Now | 87.46% | Piper Sandler | David Amsellem | $209 → $197 | Maintains | Overweight | Get Alert |
| 03/02/2022 | Buy Now | 103.63% | RBC Capital | Gregory Renza | $216 → $214 | Maintains | Outperform | Get Alert |
| 12/20/2021 | Buy Now | 90.31% | SVB Leerink | Marc Goodman | — | Maintains | Outperform | Get Alert |
| 12/17/2021 | Buy Now | 104.59% | Needham | Ami Fadia | — | Maintains | Buy | Get Alert |
| 10/08/2021 | Buy Now | 65.57% | Morgan Stanley | Jeffrey Hung | — | Maintains | Equal-Weight | Get Alert |
| 10/05/2021 | Buy Now | 90.31% | Citigroup | Navann Ty | — | Initiates | → Buy | Get Alert |
| 09/23/2021 | Buy Now | 109.34% | Needham | Ami Fadia | — | Initiates | → Buy | Get Alert |
| 08/16/2021 | Buy Now | 99.83% | HC Wainwright & Co. | Oren Livnat | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Jazz Pharmaceuticals (JAZZ) stock?
The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by UBS on July 2, 2024. The analyst firm set a price target for $113.00 expecting JAZZ to rise to within 12 months (a possible 7.53% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by UBS, and Jazz Pharmaceuticals maintained their neutral rating.
When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?
The last upgrade for Jazz Pharmaceuticals PLC happened on December 9, 2022 when Goldman Sachs raised their price target to $190. Goldman Sachs previously had a neutral for Jazz Pharmaceuticals PLC.
When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?
The last downgrade for Jazz Pharmaceuticals PLC happened on November 27, 2023 when UBS changed their price target from $170 to $135 for Jazz Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $117.00 to $113.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $105.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.